Griffin has 13+ years’ experience in project and commercialisation
management in the lifescience sector. He spent 11 years with Alltech
Biotechnology, a €2.5 billion biotech company. As part of the
operations team of SFI’s €37 million flagship Centre for Research
in Medical Devices he was involved in the strategic development and
operational execution of the centre involving business development,
networking, and fund-raising. His experience with CSD has grown the
company’s network, business plan, and commercialisation strategy.
Gorman has 20 years’ experience in molecular and cellular biology
in the field of cancer research. Dr Gorman is an authority in cancer
treatment with a deep understanding of the competitive landscape and
competitor products from a scientific and developmental standpoint.
She has a large network of clinical, academic, and industry partners,
collaborators, and colleagues. She has led several industry-academia
collaborations and a large H2020 R&D project with multiple SMEs.
Leif Eriksson is an
international expert in next generation computational drug
development with 20+ years’ R&D experience, 250+ publications,
and 4 patients filed. He is the co-founder of Swedish Pharma, C26
Bioscience, Cell Stress Discoveries, and Santium Pharma. Leif has
worked closely with the pharma industry to develop and license
molecules for commercialisation.
Samali has over 13+ years executive level experience in scientific
based business. He is a successful entrepreneur cofounding and
scaling three innovative high-tech startups. Afshin Samali has filed
seven patents in the field of cancer research. He is the director of
the National Apoptosis
Research Centre in Ireland and has a large network of academic
and industry contacts and collaborators including SMEs, MNCs,
startups and non-profit organisations. Afshin Samali has 20 years’
experience in cancer biology and drug development and has coordinated
or participated in 50+ exchequer and non-exchequer grants.